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Abstract: Malignant ascites is frequently found with various solid tumors, and no 
  established treatment options exist, apart from symptomatic paracentesis. Catumaxomab, 
a trifunctional bispecific monoclonal antibody, has two binding specificities directed 
to   epithelial cell   adhesion molecule (EpCAM) and the T cell antigen CD3. With its 
  Fc-fragment,   catumaxomab   additionally binds accessory cells, including dendritic cells, 
macrophages, and natural killer cells. The   trifunctional approach thus leads to a major 
  histocompatibility   complex-unrestricted but   specific killing of epithelial tumor cells without 
need for   preactivation or external   costimulation. Because EpCAM is expressed in most solid 
tumors, but not in tissue of   mesothelial origin, intraperitoneal treatment with catumaxomab 
is   tumor-specific.   Intraperitoneal treatment with catumaxomab resulted in a significant pro-
longation of puncture-free survival in patients with malignant ascites due to epithelial cancer. 
Catumaxomab has been approved in Europe for the intraperitoneal treatment of malignant 
ascites in patients with EpCAM-positive epithelial tumors where standard therapy is not 
available or no longer feasible.
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Introduction
Peritonitis carcinomatosa indicates the presence of malignant cells in the peritoneal 
cavity, and is a well known complication of a number of malignant diseases. As a 
result, so-called malignant ascites develops. Malignant ascites is characterized by 
positive cytology of malignant cells. Impaired lymphatic drainage by occlusion of the 
lymphatic vessels and increased fluid production causes the accumulation of malignant 
ascites in the peritoneum.1 Clinical manifestations include symptoms of abdominal 
pain, obstruction, fatigue, and abdominal swelling.
In their retrospective analysis of 209 patients with malignant ascites,   Ayantunde et al 
found a median survival time of 5.7 months after diagnosis of ascites. Independent 
negative prognostic factors were type of cancer, liver metastasis, and low serum 
albumin, and, in contrast, patients with ovarian cancer had a favorable prognosis.2
Treatment options are symptomatic, and the most common is paracentesis or 
surgical treatment, including peritoneovenous shunting. Systemic and local treatment 
options include systemic chemotherapy, intraperitoneal chemotherapy, or therapy 
with radioisotopes. Additionally, the vascular endothelial growth factor antibody 
bevacizumab is currently being tested in clinical studies to treat and prevent   malignant   







Catumaxomab (anti-EpCAM × anti-CD3) is a hybrid, 
hybridoma-derived, trifunctional, monoclonal bispecific 
antibody, combining two half-antibodies of mouse IgG2a 
and rat IgG2b that represent homologous immunoglobulin 
subclasses. Preclinical studies have shown the following 
three events to occur, demonstrating the trifunctional mode 
of action of the drug:
•	 One antigen binding site, the mouse IgG2a, recognizes 
the tumor-specific antigen4
•	 The other antigen binding site (rat IgG2b) binds to CD3, 
part of the T cell receptor complex5,6
•	 The Fc-fragment binds to FcγR Type I and III positive 
cells (eg, macrophages, dendritic cells, and natural killer 
cells) but not to inhibitory Type II FcγR (located on, eg, 
B cells).7
The stimulation of immune cells is demonstrated by 
production of cytokines, including interleukin (IL)-1β, IL-2, 
IL-6, IL-12, and the dendritic cell cytokine 1. Activated 
accessory cells, including macrophages and dendritic cells, 
induce several costimulatory signals, eg, via CD40-CD40L 
to T cells to prevent T cell anergy. The simultaneous acti-
vation of T cells and accessory immune cells, and their 
mutual stimulation, leads to specific tumor cell killing by 
induction of apoptosis, release of cytokines, and perforin-
mediated lysis, as well as antibody-dependent cellular 
cytotoxicity. Crucial in this process is the combination of 
the two potent immunoglobulin isotypes, mouse IgG2a and 
rat IgG2b, which, in contrast with other reported combina-
tions, not only bind but also activate accessory cells. The 
trifunctional approach thus leads to major histocompatibility 
complex-unrestricted but specific killing of tumor cells 
without need for preactivation or external costimulation5,8 
(see Figure 1).
EpCAM is a Type I transmembrane glycoprotein that 
mediates Ca2+-independent homophilic cell adhesions.9 In 
humans, EpCAM is expressed only in epithelium and neo-
plasms derived from epithelia.10 EpCAM is also strongly 
expressed in carcinomas of various origins, including colon, 
rectum, gastric, ovarian, esophagus, lung, pancreas, breast, 
head, and neck.11–13 Because of the wide expression on tumor 
cells, EpCAM is considered a tumor-associated antigen, and 
innovative immunotherapeutic approaches targeting EpCAM 
are of special interest. EpCAM expression is a negative 
prognostic marker for overall survival in patients suffering 
from either nodal-positive or node-negative breast cancer. 
Schmidt et al demonstrated that EpCAM overexpression was 
independently associated with poor survival in node-negative 
patients. This effect was particularly strong in the subgroup 
of triple-negative breast cancer, making EpCAM an attractive 
therapeutic target in this patient population.14,15
EpCAM has a direct impact on cell cycle and   proliferation, 
and the ability to upregulate the proto-oncogene, c-myc, and 
cyclin A/E rapidly. Furthermore, EpCAM weakens cadherin-
mediated cell adhesion, and thereby modulates prolifera-
tion, differentiation, and tissue maintenance.16 Blocking of 
EpCAM leads to a decrease in proliferation and metabolism 
in human carcinoma cells.17 Recently, Maetzel et al demon-
strated how EpCAM affects nuclear function by shedding 
of its ectodomain, EpEX, and nuclear translocation of its 
intracellular domain, EpICD, dependent on the presence 
of tumor necrosis factor-alpha-converting enzyme (TACE, 
ADAM17) and presenilin-2.18   Furthermore,   Lindhofer et al 
showed elimination of putative   EpCAM-positive cancer stem 
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Catumaxomab for malignant ascites
treated with catumaxomab.19 Recently Hirschhaeuser et al 
  demonstrated a strong, dose-dependent effect of   catumaxomab 
on   multicellular tumor spheroids of human EpCAM-positive 
FaDu tumor cells when cocultured with human peripheral 
blood monocytes in terms of volume reduction and infiltra-
tion of immune cells.20
intraperitoneal administration
The first reported clinical pilot study treated eight patients 
with malignant ascites by intraperitoneal application of catu-
maxomab or ertumaxomab binding EpCAM or human epider-
mal growth receptor 2/neu antigen on tumor cells, respectively. 
Treatment consisted of four to six applications within nine to 
23 days, using a total amount of 145–940 µg of the antibody. 
Seven of eight patients required no further paracentesis dur-
ing follow-up or until death, with a mean paracentesis-free 
interval of 38 weeks. Complete elimination of tumor cells in 
ascites was seen at total doses of 40–140 µg. Clinical response 
with disappearance of ascites accumulation was correlated 
with elimination of tumor cells (P = 0.0014).21
In a Phase I/II study reported by Burges, patients with 
malignant ascites due to ovarian cancer were treated with 
  escalating intraperitoneal doses of catumaxomab. The 
maximum tolerated dose was defined as 10, 20, 50, 200, 
and 200 µg on days 0, 3, 6, 9, and 13. The dose-limiting 
toxicities were large bowel obstruction Common Toxicity 
Criteria Grade 3 and gamma glutamyl transferase elevation 
Grade 4. All patients had treatment-emergent adverse events, 
with fever, nausea, vomiting, abdominal pain, lymphopenia, 
and general pain being the most common events. In terms 
of efficacy, 22 of 23 patients did not require any further 
paracentesis during a follow-up period of up to 37 days. 
The authors concluded that a dose regimen of 10, 20, 50, 
and 150 µg would be the recommended treatment schedule 
for further investigation.22
This led to a pivotal Phase II/III study in patients with 
symptomatic malignant ascites secondary to epithelial   cancers 
requiring symptomatic therapeutic paracentesis. The study 
compared paracentesis with intraperitoneal   catumaxomab ver-
sus paracentesis alone in a two-arm, open-label, randomized 
trial. The primary endpoint was   puncture-free survival, defined 
as the time to first need for therapeutic puncture or death after 
treatment.   Secondary endpoints were time to next paracente-
sis, ascites signs defined by the patient, ascites signs defined 
by the   investigator, and overall survival. The investigators 
were to follow an algorithm when a   paracentesis was indicated 
(ascites .1L as assessed by a computed tomography scan and 
signs and symptoms of ascites assessed by the investigator 
using physical examination and a patient questionnaire) to 
ensure a comparable decision on when to perform paracen-
tesis by the different investigators in the different treatment 
arms. Patient in the paracentesis-only treatment group were 
allowed to cross over to catumaxomab treatment if they still 
fulfilled the inclusion and exclusion   criteria, and had had at 
least two paracenteses after day 0 of the study. The percent-
age and outcome of the crossover patients were not reported, 
although they might influence the secondary endpoint of 
overall survival. Treatment consisted, as recommended, of 
four constant-rate intraperitoneal infusions at doses of 10, 
20, 50, and 150 µg of catumaxomab on days 0, 3, 7, and 10. 
The antibody was administered via intraperitoneal catheter 
in an inpatient setting, and the control group was treated 
with a paracentesis. Toxicity was as expected, with predomi-
nantly cytokine-release-like symptoms, including pyrexia 
(in 60.5% of patients), nausea, and vomiting. Ileus was 
reported in 6.4% of the patients treated with catumaxomab. 
There were no treatment-related deaths. In total, 258 patients 
were randomized, of whom 170 received catumaxomab 
and paracentesis and 88 received paracentesis alone. One 
hundred and twenty-nine patients had ovarian cancer, and 
129 patients suffered from nonovarian cancer, mostly gastric 
cancer (n = 66). The   primary endpoint of puncture-free sur-
vival was significantly prolonged in catumaxomab patients 
in both strata (ovarian: 52 versus 11 days, and nonovarian 
cancer: 37 versus 14 days, P , 0.0001,   respectively) as well 
as in the pooled analysis (46 versus 11 days). The secondary 
endpoint of median overall   survival was not prolonged in the 
pooled analysis (72 days for   catumaxomab versus 68 days 
for paracentesis only, P = 0.0846) as well as in the stratified 
groups. Subgroup analysis showed a significant (P = 0.0313) 
survival benefit for catumaxomab in the gastric cancer patients 
(71 versus 44 days). The authors concluded that the treatment 
regimen demonstrated a   clinically relevant benefit in patients 
with malignant ascites from epithelial cancer.23
Summary
Catumaxomab, given intraperitoneally in ascending,   repetitive 
doses, prolongs puncture-free survival in patients with 
  malignant ascites. Side effects are explained by the mode of 
action of the drug and are usually reversible. Common side 
effects with intraperitoneal treatment include cytokine release-
related symptoms, like fever, chills, nausea, and vomiting.
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